ID   TJU-UM001
AC   CVCL_B6PW
SY   UM001; Thomas Jefferson University-Uveal Melanoma 001
DR   cancercelllines; CVCL_B6PW
DR   Wikidata; Q112041791
RX   PubMed=24354797;
RX   PubMed=25952648;
RX   PubMed=26613897;
RX   PubMed=32430489;
CC   Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Heterozygous (PubMed=24354797; PubMed=25952648).
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=24354797; DOI=10.1111/pcmr.12206;
RA   Yoshida M., Selvan S.R., McCue P.A., DeAngelis T., Baserga R., Fujii A.,
RA   Rui H., Mastrangelo M.J., Sato T.;
RT   "Expression of insulin-like growth factor-1 receptor in metastatic
RT   uveal melanoma and implications for potential autocrine and paracrine
RT   tumor cell growth.";
RL   Pigment Cell Melanoma Res. 27:297-308(2014).
//
RX   PubMed=25952648; DOI=10.1158/0008-5472.CAN-15-0370; PMCID=PMC4490069;
RA   Cheng H.-Y., Terai M., Kageyama K., Ozaki S., McCue P.A., Sato T.,
RA   Aplin A.E.;
RT   "Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors
RT   in metastatic uveal melanoma.";
RL   Cancer Res. 75:2737-2748(2015).
//
RX   PubMed=26613897; DOI=10.1016/j.ajpath.2015.09.011; PMCID=PMC4715216;
RA   Ozaki S., Vuyyuru R., Kageyama K., Terai M., Ohara M., Cheng H.-Y.,
RA   Manser T.L., Mastrangelo M.J., Aplin A.E., Sato T.;
RT   "Establishment and characterization of orthotopic mouse models for
RT   human uveal melanoma hepatic colonization.";
RL   Am. J. Pathol. 186:43-56(2016).
//
RX   PubMed=32430489; DOI=10.1158/1535-7163.MCT-19-1016; PMCID=PMC7415561;
RA   Teh J.L.F., Purwin T.J., Han A., Chua V., Patel P., Baqai U., Liao C.,
RA   Bechtel N., Sato T., Davies M.A., Aguirre-Ghiso J.A., Aplin A.E.;
RT   "Metabolic adaptations to MEK and CDK4/6 cotargeting in uveal
RT   melanoma.";
RL   Mol. Cancer Ther. 19:1719-1726(2020).
//